Enovis (ENOV) to Release Quarterly Earnings on Thursday

Enovis (NYSE:ENOV) will be announcing its earnings results before the market opens on Thursday, May 2nd. Analysts expect the company to announce earnings of $0.50 per share for the quarter. Enovis has set its FY 2024 guidance at 2.500-2.650 EPS and its FY24 guidance at $2.50-$2.65 EPS.Investors interested in participating in the company’s conference call can do so using this link.

Enovis (NYSE:ENOV) last posted its earnings results on Thursday, February 22nd. The company reported $0.79 EPS for the quarter, topping analysts’ consensus estimates of $0.76 by $0.03. The business had revenue of $455.00 million during the quarter, compared to analyst estimates of $444.34 million. Enovis had a positive return on equity of 3.84% and a negative net margin of 1.95%. The company’s quarterly revenue was up 11.2% compared to the same quarter last year. During the same quarter last year, the company earned $0.72 EPS. On average, analysts expect Enovis to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Enovis Stock Up 1.3 %

Enovis stock opened at $56.17 on Thursday. The company has a current ratio of 2.43, a quick ratio of 1.16 and a debt-to-equity ratio of 0.14. Enovis has a 12 month low of $43.04 and a 12 month high of $66.14. The firm has a market cap of $3.08 billion, a price-to-earnings ratio of -92.10 and a beta of 1.97. The stock has a fifty day simple moving average of $60.10 and a two-hundred day simple moving average of $55.47.

Analysts Set New Price Targets

Several analysts recently commented on the company. Canaccord Genuity Group lifted their price objective on Enovis from $73.00 to $75.00 and gave the stock a “buy” rating in a report on Friday, February 23rd. UBS Group assumed coverage on Enovis in a report on Monday, January 22nd. They issued a “buy” rating and a $75.00 price objective for the company. Stephens assumed coverage on Enovis in a report on Tuesday, February 13th. They issued an “overweight” rating and a $72.00 price objective for the company. Needham & Company LLC reaffirmed a “buy” rating and issued a $82.00 price objective on shares of Enovis in a report on Wednesday, April 10th. Finally, Wells Fargo & Company boosted their price target on Enovis from $73.00 to $79.00 and gave the company an “overweight” rating in a report on Friday, February 23rd. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat, Enovis has an average rating of “Buy” and a consensus target price of $75.43.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.